MedTrace Logo

Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

NCT02133079 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-11

No results posted yet for this study

Summary

To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and Pancreatic Adenocarcinoma

Conditions

Interventions

BIOLOGICAL

autologous gp96 vaccination

vaccination of autologous gp96 derived from tumor tissue + basal treatment

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Cure&Sure Biotech Co., LTD

    lead INDUSTRY

Principal Investigators

  • Jianqiang Cai, meidical · Cancer Insititute and Hospital,Chinese Academy of Medical Sciences

  • Lei Yu, medical · Cancer Insititute and Hospital,Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-11-30
Completion
2019-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133079 on ClinicalTrials.gov